Compare LyondellBasell Industries NV (LYB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Recursion Pharmaceuticals Inc — how do they compare? LyondellBasell Industries NV trades at $60.34 (market cap $19.49B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: LyondellBasell Industries NV is far larger — about 9.1× Recursion Pharmaceuticals Inc's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| LYB | RXRX | |
|---|---|---|
Market Cap | $19.49B | $2.14B |
Volume | 6,033,396 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $6.79 |
52-Week Low | $42.28 | $2.84 |
Typical Hold Time | 87 Days | 22 Days |
Enterprise Value | $31.08B | $1.66B |
Dividend Yield | 4.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell (LYB) trades at $58.49, down 0.75% on the day, amid a bearish technical signal and mixed fundamentals. The company reported a net loss of $745 million in 2025, with negative profit margins, though recent quarterly EPS beats and a consensus price target of $69.38 suggest recovery potential. Cash flow remains positive, and a $0.69 dividend is scheduled for payment on August 31, 2026, but declining revenue and high debt levels pose challenges.
The outlook for LYB hinges on earnings recovery and cost management, with analyst sentiment evenly split between buy and hold. Key risks include volatile chemical markets and high leverage, while institutional activity shows mixed positioning. The stock offers value based on P/S and P/B ratios but requires monitoring of profitability trends and debt sustainability for sustained upside.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
